Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Good News
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Dec 30, 2020 11:45am
165 Views
Post# 32197482

RE:RE:RE:RE:Good News

RE:RE:RE:RE:Good News
themagicbox wrote: Not to mention the new research coming out of the "university-that-cannot-be-named" discussed in the latest biopub. That will create both new IP and new patents that go far beyond the data protection and organge book patents for Oten/346.

The wild card will be what comes from the research on covid and if the different pipeline drugs have a therapeutic effect on COVID 


I find COVID to be an interesting topic based on a few facts ...
1.  They can't discuss details (other than an NDA, what other reason?).  Could there be a partnership on this side.
2.  Antibe is looking to get deeper into gaseous mediators and this alone spells exciting new approaches to dealing with inflamation, the root cause in some respects.
3.  Think viruses and think gaseous mediators and I'm picturing opportunities for any virus down the road - even the common flu ?????  Ya ya ... I'm dreaming - but Wallace has a chance to live his dream ... right here ... right now !!!!
4.  https://journals.physiology.org/doi/full/10.1152/ajpcell.00187.2020

Wonderdrug possibilites?  I think one day we will look at gaseous mediators and say - what took us so long to get here ?  Fingers crossed.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities